Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapiesnews2025-10-15T13:00:10+00:00October 15th, 2025|Endpoints News|
Former FDA deputy Bumpus to lead Charles River’s new scientific advisory boardnews2025-10-15T12:08:48+00:00October 15th, 2025|Endpoints News|
Post-Hoc Live: Are the good times in biotech … back?news2025-10-15T11:33:01+00:00October 15th, 2025|Endpoints News|
Bexorg raises $23M to test drugs on ‘rebooted’ human brains from organ donorsnews2025-10-15T11:00:50+00:00October 15th, 2025|Endpoints News|
Which big pharma had the busiest M&A team? Q3 biopharma deal analysisnews2025-10-15T11:00:20+00:00October 15th, 2025|Endpoints News|
Mark Pruzanski joins Alentis as CEO after leading Intercept and Versanisnews2025-10-15T11:00:15+00:00October 15th, 2025|Endpoints News|
Hair loss biotech Pelage collects $120M for Phase 3 trialsnews2025-10-15T11:00:14+00:00October 15th, 2025|Endpoints News|
Tubulis snags $361M for clinical-stage ADCsnews2025-10-15T09:00:17+00:00October 15th, 2025|Endpoints News|
Reinventing mental healthcare in the age of AInews2025-10-14T19:21:11+00:00October 14th, 2025|Endpoints News|
Pfizer claims first-line success for Tukysa in breast cancer Phase 3 trialnews2025-10-14T18:22:10+00:00October 14th, 2025|Endpoints News|
